Bipartisan leaders of the House Energy and Commerce Committee introduced a comprehensive legislative package to reauthorize the Food and Drug Administration (FDA) user fee agreements. The package included provisions to strengthen the accelerated approval process and increase diversity of clinical trials.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
From April 4-8, U.S. members of the Association for Clinical Oncology (ASCO) participated in the 2022 ASCO Week of Action, which was held in conjunction with the Association’s annual Advocacy Summit. During the Week of Action, advocates from across the country sent a record 920 letters to Members of Congress through ASCO’s ACT Network urging them to take action on important policies to improve access to high-quality, equitable care for people with cancer. During the Advocacy Summit 132 ASCO members from 43 states and the District of Columbia held nearly 200 virtual meetings with Members of Congress and staff to urge action on the same issues.
Congress is considering several cancer policy priorities this week, including the PREVENT Pandemics Act, Cures 2.0, and legislation to authorize ARPA-H.
The Association for Clinical Oncology (ASCO) is holding its annual Advocacy Summit Week of Action from April 4-8, during which ASCO members are encouraged to connect with their Members of Congress about policies and legislation that impact cancer care and research.
The Fiscal Year 2022 omnibus funding bill provides $45 billion for the National Institutes of Health (NIH), including $6.9 billion for the NCI. The Association for Clinical Oncology (ASCO) commends Congress for their enthusiastic, bipartisan support for continued investment in biomedical research.
The Association for Clinical Oncology (ASCO) sent a letter to members of the U.S. House of Representatives and U.S. Senate endorsing the Provider Relief Fund Improvement Act (H.R. 5963/S. 3611).
The Association for Clinical Oncology (ASCO), along with more than 20 other stakeholder groups, sent a letter to congressional leadership urging lawmakers in both chambers to pass legislation this year to help radiation therapy clinics continue to provide potentially life-saving care to patients with cancer.
The Association for Clinical Oncology (ASCO) joined with more than 100 organizations to urge Congress to support President Biden’s reinvigorated Cancer Moonshot and to allocate funding to support the initiative.